Hypoxia occurs in tumors as a result of the poor ability of their disorganized vascular networks to deliver blood borne oxygen. HypoxiSense detects the tumor cell surface expression of carbonic anhydrase 9 (CA IX) protein, which increases in hypoxic regions within many tumors, especially in cervical, colorectal, non-small cell lung tumors. Pairing HypoxiSense with optical fluorescent imaging technology allows you to image and quantitate tumor sub-regions undergoing hypoxia-related changes, non-invasively and in vivo.

HypoxiSense is ideally suited for detecting hypoxia-induced changes in CA IX expression during:

- Imaging in vivo mouse and rat tumors
- Assessing therapeutic efficacy in drug screening of tumor models
- Fluorescence microscopy of disease tissues

For the first time, hypoxia can be measured non-invasively in living mice and rats, as well as in ex vivo tissue samples. It’s the perfect solution for the in vivo hypoxia researcher.

HeLa cervical cancer tumor cells were implanted in two subcutaneous sites on the upper mammary fat pads of a nude mouse and allowed to grow to 600 mm³. Simultaneous imaging with HypoxiSense 680 and AngioSense® 750 in living mice reveals that both tumor hypoxia and vascular leak are occurring in both tumors. As expected, coronal slices of tomographic imaging datasets further show discrete regions of hypoxia throughout the tumors that do not co-localize with the sites of vascular leak typically associated with angiogenesis.
HypoxiSense enables imaging of tumor hypoxia in both tomographic (subcutaneous and deep tissue tumors) and planar (subcutaneous tumors) optical imaging systems. A representative mouse, bearing surface HeLa cervical cancer tumor xenografts, was injected intravenously with HypoxiSense and imaged 24h later using the FMT® 2500 Fluorescence Molecular Tomography imaging (left) and planar reflectance imaging (right).

HypoxiSense 680 clears from the bloodstream quickly, with a half-life of approximately 4 minutes, yet it accumulates within hypoxic regions in tumor tissue with a half-life of 6h. Tumor hypoxia can be detected as early as 3h post-HypoxiSense injection, with optimal signal to noise measured at 12-24h once circulating agent has completely cleared.

HypoxiSense is optimized for use on PerkinElmer FMT Quantitative Pre-clinical Imaging Systems, which enable deep tissue interrogation of biomarkers and disease mechanisms.

### Name Description Part Number

| HypoxiSense 680 | Fluorescent Pre-clinical Imaging Agent, 10 mouse doses | NEV11070 |
| HypoxiSense 680 trial | Fluorescent Pre-clinical Imaging Agent, trial size | NEV11072 |

For more information, please visit: www.perkinelmer.com/hypoxia

---

For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs

Copyright © 2011, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners.

009849_01 Printed in USA Sept. 2011